top of page

Publication Highlights

april 2025

GLOBODY APPLICATIONS

COVID-19 exposure risks and protective measures in East London’s healthcare and academic sectors: Insights and applications of GloBody technology for infectious disease monitoring

april 2025

MS Therapy

Clinical opinions and case studies on understanding and managing hypogammaglobulinaemia in multiple sclerosis: United Kingdom perspective

june 2024

Antibody Immunogenicity

Immunogenicity of biologics used in the treatment of asthma

May 2024

Antibody discovery

Eukaryotic ribosome display for antibody discovery: A review

Dec 2023

MS Therapy

Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis

July 2023

INFECTION & IMMUNOBIOLOGY

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

MARCH 2023

MICROBIAL PATHOGENESIS

Exploring the “N-Terminal Anchor” Binding Interface of the T3SS Chaperone–Translocator Complexes from P. aeruginosa

JUNE 2022

infection & immunobiology

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

december 2021

MS THERAPY

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in MS

bottom of page